Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 10, Issue 12, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-05
DOI
10.1038/s41419-019-2156-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genetic characterization of ABT-199 sensitivity in human AML
- (2019) Richard Bisaillon et al. LEUKEMIA
- Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia
- (2018) Brenda Chyla et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells
- (2018) Mohamed Rahmani et al. CANCER RESEARCH
- BCL-2 inhibition in AML: an unexpected bonus?
- (2018) Marina Konopleva et al. BLOOD
- BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL
- (2018) Georgia Greaves et al. CELL DEATH AND DIFFERENTIATION
- A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia
- (2018) Haley E. Ramsey et al. Cancer Discovery
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
- (2018) Delphine Merino et al. CANCER CELL
- Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
- (2017) Delphine Merino et al. Science Translational Medicine
- Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
- (2016) X. Niu et al. CLINICAL CANCER RESEARCH
- Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane
- (2016) Katelyn L. O'Neill et al. GENES & DEVELOPMENT
- HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia
- (2016) M Kontro et al. LEUKEMIA
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells
- (2016) C Safferthal et al. ONCOGENE
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
- (2016) Kevin H. Lin et al. Scientific Reports
- Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells
- (2015) Sofie Steinwascher et al. CANCER LETTERS
- Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells
- (2015) Haiming Dai et al. GENES & DEVELOPMENT
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
- (2014) Liran I. Shlush et al. NATURE
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis
- (2013) L Steinhart et al. Cell Death & Disease
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- BH3 Domains other than Bim and Bid Can Directly Activate Bax/Bak
- (2010) Han Du et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
- (2008) Cheol-Min Park et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now